BRONCHITOL GRANTED ORPHAN DRUG STATUS IN EUROPE

Pharmaxis Ltd announced today that the European Medicines Agency (EMEA) has granted Orphan designation to the company's product Bronchitol(TM), for the treatment of cystic fibrosis. Orphan designation has been granted on the basis of Bronchitol's potential to treat cystic fibrosis, a genetic disease which, for the patient, is characterised by recurring respiratory complications.

DG News (http://www.docguide.com/news/content.nsf/news/8525697700573E18852570B900637E76)